On the stock market since 2025, it operates in the world of health and science. It has 849 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 43% a year over the last 3 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 43% a year on average.
Sales run at $260.2M a year. A small number, but proof the product has real buyers.
There is $222.0M in the vault; even if every debt were paid off, $222.0M would remain.
A loss of $12.8M against $260.2M in annual sales.
On our five-subject report card, OMDA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OMDA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.